| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share |
| 06 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Partici... |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No. 2 (the “Amendment No. 2”) to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (“Board”) of STAAR Surgical Company, a Delaware corporation (... |
| 09 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of STAAR Surgical Company (the “Company”) approved an increase to the annual base salary of Deborah Andrews, the Company's Interim Co-Chief Executive... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share |
| 08 Apr 2026 |
8-K: Regulation FD Disclosure
LAKE FOREST, CA, April 8, 2026 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for th... |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation |
| 05 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 4, 2026, STAAR Surgical Company (the “Company”) entered into a letter agreement with Nathaniel Sisitsky, the Company’s Chief Legal Officer and Corporate Secretary (the “Letter Agreement”), that provides for Mr. Sisitsky’s ter... |
| 02 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Lake Forest, CA, February 2, 2026 --- STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announce... |
| 16 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 15, 2026, the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) elected a new Board Chair, approved changes to the composition and leadership of the Board’s three standing committees, and established t... |
| 15 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +2 more
This letter agreement (this “Agreement”), effective as of January 14, 2026 (the “Effective Date”), is intended to memorialize the understandings and agreements that have been reached between STAAR Surgical Company (the “Company”) and Bro... |
| 06 Jan 2026 |
8-K: Termination of a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders
As previously disclosed, on August 4, 2025, STAAR Surgical Company (the “Company”) entered into an Agreement and Plan of Merger, dated as of August 4, 2025 (as amended, the “Merger Agreement”), by and among the Company, Alcon Research, L... |
| 06 Jan 2026 |
8-K: Other Events
LAKE FOREST, CA, January 6, 2026 – STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminar... |
| 09 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
This Amendment No. 2, dated as of December 9, 2025 (this “Amendment”), to the Agreement and Plan of Merger, dated as of August 4, 2025 (the “Initial Agreement”), as amended, is by and among Alcon Research, LLC, a Delaware limited liabili... |
| 08 Dec 2025 |
8-K: Other Events
Results of Go-Shop Process Validate the Effectiveness of the STAAR Board’s Process |
| 07 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Amendment No. 1, dated as of November 7, 2025 (this “Amendment”), to the Agreement and Plan of Merger, dated as of August 4, 2025 (the “Agreement”), is by and among Alcon Research, LLC, a Delaware limited liability company (“Parent”... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
LAKE FOREST, CA, November 5, 2025 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quar... |
| 27 Oct 2025 |
8-K: Other Events
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon |
Loading...